JPH02111714A - Cosmetic - Google Patents
CosmeticInfo
- Publication number
- JPH02111714A JPH02111714A JP26503488A JP26503488A JPH02111714A JP H02111714 A JPH02111714 A JP H02111714A JP 26503488 A JP26503488 A JP 26503488A JP 26503488 A JP26503488 A JP 26503488A JP H02111714 A JPH02111714 A JP H02111714A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- cosmetic
- potassium alum
- perfumery
- compounding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 19
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 claims abstract description 15
- 239000002253 acid Substances 0.000 claims abstract description 13
- 235000011126 aluminium potassium sulphate Nutrition 0.000 claims abstract description 13
- 229940050271 potassium alum Drugs 0.000 claims abstract description 13
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 8
- 206010000496 acne Diseases 0.000 abstract description 9
- 239000006210 lotion Substances 0.000 abstract description 9
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 239000006071 cream Substances 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 239000003921 oil Substances 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 5
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 4
- 201000005884 exanthem Diseases 0.000 abstract description 4
- 229930195729 fatty acid Natural products 0.000 abstract description 4
- 239000000194 fatty acid Substances 0.000 abstract description 4
- 150000004665 fatty acids Chemical class 0.000 abstract description 4
- 206010037844 rash Diseases 0.000 abstract description 4
- 208000010201 Exanthema Diseases 0.000 abstract description 3
- 206010016936 Folliculitis Diseases 0.000 abstract description 3
- 206010027627 Miliaria Diseases 0.000 abstract description 3
- 150000001298 alcohols Chemical class 0.000 abstract description 2
- 150000001413 amino acids Chemical class 0.000 abstract description 2
- 150000001735 carboxylic acids Chemical class 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 150000002148 esters Chemical class 0.000 abstract description 2
- 229930195733 hydrocarbon Natural products 0.000 abstract description 2
- 150000002430 hydrocarbons Chemical class 0.000 abstract description 2
- 235000014593 oils and fats Nutrition 0.000 abstract description 2
- 239000000344 soap Substances 0.000 abstract description 2
- 239000004094 surface-active agent Substances 0.000 abstract description 2
- 235000013343 vitamin Nutrition 0.000 abstract description 2
- 239000011782 vitamin Substances 0.000 abstract description 2
- 229940088594 vitamin Drugs 0.000 abstract description 2
- 229930003231 vitamin Natural products 0.000 abstract description 2
- 229920003169 water-soluble polymer Polymers 0.000 abstract description 2
- 239000001993 wax Substances 0.000 abstract description 2
- 238000013329 compounding Methods 0.000 abstract 2
- 229940103272 aluminum potassium sulfate Drugs 0.000 abstract 1
- 239000003925 fat Substances 0.000 abstract 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 abstract 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 24
- 230000000052 comparative effect Effects 0.000 description 12
- 229960001340 histamine Drugs 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 10
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 235000019626 lipase activity Nutrition 0.000 description 7
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000002874 Acne Vulgaris Diseases 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 208000020154 Acnes Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 241000186427 Cutibacterium acnes Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 108010062580 Concanavalin A Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 229920002055 compound 48/80 Polymers 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/26—Aluminium; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Description
【発明の詳細な説明】 (産業上の利用) 本発明は抗炎症効果を有する化粧料に関する。[Detailed description of the invention] (Industrial use) The present invention relates to cosmetics having anti-inflammatory effects.
(従来の技術)
カリミョウバンは、 タンパク質と結合してこれを凝固
させることで局所収れん作用を有することが知られてい
る。このため化粧料では、アストリンゼントなどの化粧
水、スキントニツ久 アフターシェーブローション、洗
顔剤、浴剤などに用いられている。(Prior Art) Potassium alum is known to have a local astringent effect by binding to proteins and coagulating them. For this reason, it is used in cosmetics such as lotions such as Astringent, aftershave lotions, facial cleansers, and bath additives.
酸は、化粧料では主にpHa整に用いられている。Acids are mainly used in cosmetics to adjust pH.
(発明が解決しようとする問題点)
化粧料である特定の効果を持たせようとする場合、特定
の薬剤を配合させなくてはいけない。しかし薬剤を配合
することで、皮膚トラブルの原因となったり、ベースの
経時安定性が著しく低下したりすることがある0例えば
、抗炎症剤としてニキビ用化粧料に配合されるサルファ
剤は、経時的に変臭を起こしたり、ベースの変色を起こ
したりする等の問題があった。(Problems to be Solved by the Invention) If cosmetics are to have a specific effect, a specific drug must be added to the cosmetic. However, adding drugs can cause skin problems or significantly reduce the stability of the base over time.For example, sulfa drugs, which are added to acne cosmetics as anti-inflammatory agents, There were problems such as a change in odor and discoloration of the base.
(問題を解決するための手段)
本発明者等は、鋭意研究を重ねた結果、カリミョウバン
及び酸を化粧品に特定の割合で配合することで、抗炎症
効果があることを見い出し、さらに研究した結果1本発
明を完成するに至った。(Means for Solving the Problem) As a result of intensive research, the present inventors discovered that combining potassium alum and acid in cosmetics in a specific ratio has an anti-inflammatory effect, and conducted further research. Result 1 The present invention was completed.
本発明は、カリミョウバン及び酸を含有することを特徴
とする抗炎症効果を有する化粧料に関する。TECHNICAL FIELD The present invention relates to a cosmetic having an anti-inflammatory effect characterized by containing potassium alum and an acid.
本発明で使用するカリミョウバンとは、化学名硫酸アル
ミニウムカリウムのことである。The potassium alum used in the present invention has the chemical name potassium aluminum sulfate.
本発明で使用する酸は、化粧品で使用されるもであり、
カルボン酸としては、マロン酸、 クエン酸、シュウ酸
、 コハク酸、 フマル酸、 リンゴ酸、酒石酸、乳酸
、 ピロリドンカルボン酸等、 アミノ酸としては、ア
スパラギン酸、 グルタミン酸等が挙げられる。The acid used in the present invention is one used in cosmetics,
Examples of carboxylic acids include malonic acid, citric acid, oxalic acid, succinic acid, fumaric acid, malic acid, tartaric acid, lactic acid, and pyrrolidone carboxylic acid. Examples of amino acids include aspartic acid and glutamic acid.
本発明で言う抗炎症効果とは、ニキビ、毛包炎(おでき
)、かぶれ、あせも等の吹出物の原因である炎症を抑え
る作用のことをいう。 ニキビ、かぶれ、毛包炎(お
でき)、あせも等の吹出物は皮膚中での炎症が原因で引
き起こされる。これらの炎症の原因には、いろいろなも
のがある。たとえば1毛包内につまった皮脂がニキビ原
因菌Pr。The anti-inflammatory effect as used in the present invention refers to the effect of suppressing inflammation that causes pimples such as acne, folliculitis (boils), rashes, and heat rash. Pimples such as acne, rash, folliculitis (boils), and heat rash are caused by inflammation in the skin. There are many causes of these inflammations. For example, the sebum trapped within a hair follicle is Pr, the acne-causing bacteria.
pionibacterium acnes (以
後P、 acnes)などの細菌の産生ずるリパーゼに
よって分解され遊離される脂肪酸の刺激によるものや、
黄色ブドウ球菌が手孔に感染して化膿するものや、皮膚
組織の肥満細胞からヒスタミンが遊離され毛細血管を拡
張して紅斑が生じたり、毛細血管透過性亢進により血管
から血しょう蛋白や水分が組織に流れ出すという原因に
より生じるものがある。Stimulation of fatty acids that are broken down and liberated by lipase produced by bacteria such as Pionibacterium acnes (hereinafter referred to as P acnes);
Staphylococcus aureus infects the hand and causes suppuration, histamine is released from mast cells in the skin tissue and dilates the capillaries, causing erythema, and increased capillary permeability causes plasma proteins and water to drain from the blood vessels. There are some that are caused by leakage into the tissue.
本発明の化粧料とは、油脂類、ロウ類、炭化水素類、脂
肪酸類、アルコール類、エステル類、アミン・アミド・
金属セッケン、界面活性剤等の油脂加工製品、香料、ガ
ム質及び水溶性高分子化合物、あるいはビタミン類など
を基材として製造される加工製品をいう。The cosmetics of the present invention include oils and fats, waxes, hydrocarbons, fatty acids, alcohols, esters, amines, amides,
Processed products manufactured from processed oil products such as metal soaps, surfactants, fragrances, gums, water-soluble polymer compounds, vitamins, etc.
これらの基剤を原料として製造される加工製品としては
、化粧水、乳液、 クリーム、 リップクリーム、 口
紅、 ファンデーション、香水、 オーデコロンなどが
挙げられる。Processed products manufactured using these base materials include lotions, milky lotions, creams, lip balms, lipsticks, foundations, perfumes, and colognes.
本発明の化粧料に配合するカリミョウバン及び酸の使用
量は、カリミョウバン 0.001−10重量パーセン
ト、酸0.001−10重量パーセント重量パーセン好
配しくは、 カリミョウバン 0.01〜5重量パーセ
ント、酸0.01〜5重量パーセントの割合になるよう
に配合される。The amount of potassium alum and acid used in the cosmetic composition of the present invention is preferably 0.001-10% by weight of potassium alum, 0.001-10% by weight of acid, preferably 0.01-5% by weight of potassium alum. %, and the acid is blended at a ratio of 0.01 to 5% by weight.
またカリミョウバン及び酸の添加方法については、予め
水溶液にしておいて製造途中で添加してもよく、作業性
を考えて適宜選択すればよいが、製品中で均一になって
いれば良い。Regarding the method of adding potassium alum and acid, they may be prepared in advance as an aqueous solution and added during production, or may be selected as appropriate in consideration of workability, but it is sufficient that they are uniform throughout the product.
(発明の効果)
以下に実験例、実施例を挙げて本発明をさらに具体的に
説明する。本発明は、これにより限定されるものでない
。なお数値は、特に断わりのないかぎり重量パーセント
を示す。(Effects of the Invention) The present invention will be explained in more detail below with reference to experimental examples and examples. The present invention is not limited thereby. Note that the numerical values indicate weight percent unless otherwise specified.
本発明の抗炎症効果を有する化粧料について、吹出物の
炎症の原因に注目して、それに対する効果を測定した。The effects of the anti-inflammatory cosmetics of the present invention on the cause of inflammation in pimples were measured.
効果として、抗菌力、 リパーゼ活性阻害、ヒスタミン
遊離抑制、抗酸化力について試験を行った。また実際に
使用試験を行って、吹出物に対する効果を評価した。Tests were conducted on antibacterial activity, inhibition of lipase activity, suppression of histamine release, and antioxidant activity. In addition, actual use tests were conducted to evaluate the effect on breakouts.
1、抗菌力試験
a、ニキビ原因菌(P、 acnes)を用いた方法
試験管に嫌気性菌用ブイヨン培地を秤量し、そこへ試料
及び蒸留水を用い指定濃度になるように調整する。滅菌
後P、 acnesの菌液を添加し、37℃で静置培養
する。培養後、試験管の濁りを観察し抗菌力があるかを
判定した。1. Antibacterial activity test a, method using acne-causing bacteria (P, acnes) Weigh the anaerobic bacteria broth medium into a test tube, and adjust it to the specified concentration using the sample and distilled water. After sterilization, P. acnes bacterial suspension is added and cultured at 37°C. After culturing, the turbidity of the test tube was observed to determine whether it had antibacterial activity.
b、黄色ブドウ球菌を用いた方法
試験管にトリプトソイブイヨンの固型粉体を秤量し、そ
こに試料及び蒸留水を用い指定濃度になるように調整す
る。滅菌後黄色ブドウ球菌を添加し37℃で静置培養す
る。培養後、試験管の濁りを観察し抗菌力があるかを判
定した。b. Method using Staphylococcus aureus Weigh the solid powder of trypto soy broth into a test tube, and adjust it to the specified concentration using the sample and distilled water. After sterilization, Staphylococcus aureus is added and cultured at 37°C. After culturing, the turbidity of the test tube was observed to determine whether it had antibacterial activity.
(参考資料 CIIEMOTHERAPY Jan、1
981Jo129.No176〜79)
2、 リパーゼ活性阻害試験
基質としてオリーブ油を用い、 リパーゼ及び試料を添
加して、 リパーゼ作用によって遊離した脂肪酸をアル
カリ滴定して定量し、コントロールとの比較によってリ
パーゼ活性阻害効果を測定した。(Reference material CIIEMOTHERAPY Jan, 1
981Jo129. No. 176-79) 2. Lipase activity inhibition test Using olive oil as a substrate, lipase and a sample were added, fatty acids liberated by lipase action were quantified by alkaline titration, and the lipase activity inhibition effect was measured by comparison with a control. .
(酵素利用ハンドブッ久 地人書館、小崎道跣230〜
233)
3、 ヒスタミン遊離抑制試験
ラットより取り出し分離した肥満細胞を用いて、試料、
肥満細胞及びヒスタミン遊離物質を混合して肥満細胞よ
り遊離されるヒスタミンを定量し、コントロールとの比
較によってヒスタミン遊離抑制効果を測定した。ヒスタ
ミン遊離物質としては、コンカナバリンA(以後Con
、A)とコンパウンド48/80(以後Co m p、
48 / 80 )を用いた。(Enzyme Utilization Handbook, Chijin Shokan, 230 Michihin, Kozaki)
233) 3. Histamine release inhibition test Using mast cells taken out and isolated from rats, samples,
Mast cells and a histamine-releasing substance were mixed, the amount of histamine released from the mast cells was quantified, and the inhibitory effect on histamine release was determined by comparison with a control. Concanavalin A (hereinafter referred to as Concanavalin A) is a histamine-releasing substance.
, A) and Compound 48/80 (hereinafter Comp.
48/80) was used.
(生薬学雑誌、 37(4)、374〜380.19
83)4、抗酸化試験
リノール酸の自動酸化により、生成する過酸化物によっ
てFe”がFe”・になる、 これがN Ha
S CN と反応して赤色のロダン鉄Fe(SCN)
aを生成するので、その吸光度から過酸化物の量を測定
した。(Pharmaceutical Journal, 37(4), 374-380.19
83) 4. Antioxidant test Due to the autooxidation of linoleic acid, Fe" becomes Fe" due to the peroxide produced. This is N Ha
Red Rodan iron Fe (SCN) reacts with S CN
The amount of peroxide was measured from its absorbance.
(^gric Biol、Chem、 45(3)、
735〜739.1981)表1(実施例1〜3)及び
表2(比較例1〜3)の化粧水の製造方法は表1.2に
示す配合組成で、1のエタノールに2〜5と9 (BH
T)を溶解したものと10の精製水に6〜8を溶解した
ものを混合し化粧水を得た。(^gric Biol, Chem, 45(3),
735-739.1981) Table 1 (Examples 1-3) and Table 2 (Comparative Examples 1-3) The manufacturing method of the lotions is as shown in Table 1.2, and the composition is 1 part ethanol, 2-5 parts 9 (BH
A lotion was obtained by mixing a solution of T) and a solution of 6 to 8 in purified water of 10.
表3は、表1(実施例1〜3)と表2(比較例1〜3)
について、抗酸化試験を行った結果を示したものである
。実施例1〜3は、抗酸化剤としてよく知られているB
HTを配合した比較例3と比べても、時間的な吸光度変
化であまり差はな(、実施例1〜3は抗酸化作用がある
ことがわかる。Table 3 is Table 1 (Examples 1-3) and Table 2 (Comparative Examples 1-3)
The results of an antioxidant test are shown for the following. Examples 1 to 3 are based on B, which is well known as an antioxidant.
Even when compared with Comparative Example 3 in which HT was blended, there is not much difference in the change in absorbance over time (It can be seen that Examples 1 to 3 have an antioxidant effect.
実施例1〜3に比べて、カリミョウバン抜きの比較例1
.酸抜きの比較例2は、抗酸化作用がほとんどないこと
がわかる。Comparative example 1 without potassium alum compared to Examples 1 to 3
.. It can be seen that Comparative Example 2, which was acid removed, has almost no antioxidant effect.
表4は、表1(実施例1〜3)と表2(比較例1〜2)
についてリパーゼ活性阻害試験を行った結果を示した。Table 4 is Table 1 (Examples 1-3) and Table 2 (Comparative Examples 1-2)
The results of a lipase activity inhibition test are shown below.
実施例1〜3のリパーゼ活性阻害率は、 50%以上で
ありかなり高い効果があることがわかる。これと比べて
、比較例1〜2のリパーゼ活性阻害率は、 6%以下で
効果がほとんどないことがわかる。The lipase activity inhibition rates of Examples 1 to 3 were 50% or more, indicating that they were quite effective. In comparison, the lipase activity inhibition rates of Comparative Examples 1 and 2 were 6% or less, indicating that there was almost no effect.
表5の乳液の製造方法としては、油相(1〜6のもの)
を70℃で加熱溶解し、その中に予め7に8〜12を加
熱溶解し70℃まで加温したものを撹はんしながら添加
し乳化する。これを30℃まで冷却して乳液を得た。As for the manufacturing method of the emulsion in Table 5, the oil phase (1 to 6)
is heated and dissolved at 70°C, and into the solution, 7 and 8 to 12 are dissolved in advance by heating and heated to 70°C, and then added with stirring to emulsify. This was cooled to 30°C to obtain a milky lotion.
表6.7は1表5(実施例4.5と比較例4゜5)につ
いて、P、acnes菌と黄色ブドウ球菌に対する抗菌
力試験を行った結果を示す、この結果より、実施例4.
5は、いずれも試料濃度70%以上でP、acnes菌
及び黄色ブドウ球菌に対して抗菌力を示した。 しかし
比較例4.5は、いずれの試料濃度でもP、acnes
菌及び黄色ブドウ球菌に対して抗菌性を示さなかった。Table 6.7 shows the results of an antibacterial activity test against P. acnes and Staphylococcus aureus for Table 1 and Table 5 (Example 4.5 and Comparative Example 4.5).
No. 5 exhibited antibacterial activity against P. acnes and Staphylococcus aureus at sample concentrations of 70% or higher. However, in Comparative Example 4.5, P, acnes
It did not show antibacterial activity against bacteria and Staphylococcus aureus.
表8は、表5(実施例4.5と比較例4,5)について
、ヒスタミン遊離抑制効果を測定した。In Table 8, the histamine release inhibiting effect was measured for Table 5 (Example 4.5 and Comparative Examples 4 and 5).
実施例4.5は、ヒスタミン遊離物質Con、A及びC
omp、48/80いずれの場合でもヒスタミン遊離抑
制率が、 90%以上で効果が高かった。しかし比較例
4.5では、いずれも6%以下でヒスタミン遊離抑制効
果はなかった。Example 4.5 shows that histamine releasing substances Con, A and C
In both cases of omp and 48/80, the histamine release inhibition rate was 90% or more, indicating high effectiveness. However, in Comparative Examples 4.5, the concentrations were all 6% or less, and there was no effect of inhibiting histamine release.
表9のクリームの製造方法は1表5の乳液と同様の方法
で、油相(1〜5のもの)を70℃で加熱溶解し、予め
70℃に加熱溶解した水相(6〜11のもの)を油相に
撹はんしながら添加し乳化する。これを30℃まで冷却
してクリームを得た。The cream in Table 9 was manufactured in the same manner as the emulsion in Table 1, by heating and dissolving the oil phase (1 to 5) at 70°C, and then heating and dissolving the aqueous phase (6 to 11), which had been previously heated and dissolved at 70°C. Add to the oil phase while stirring and emulsify. This was cooled to 30°C to obtain cream.
表10は、表9(実施例6.7と比較例6.7)の使用
試験を行った結果を示したものである。被験者は吹出物
で悩んでいる人、使用期間は2週間使用してもらい、使
用前後での吹出物にへの効果をみた。吹出物に対する効
果は、表10の下記した方法で評価した。この結果から
、実施例6,7は吹出物に対してかなり高い効果がある
ことがわかる。Table 10 shows the results of the use tests shown in Table 9 (Example 6.7 and Comparative Example 6.7). The test subjects were people who were suffering from breakouts, and they used the product for two weeks to see the effect on breakouts before and after use. The effect on breakouts was evaluated by the method shown below in Table 10. From this result, it can be seen that Examples 6 and 7 are quite effective against breakouts.
(以下余白) 衆IX敷」 表3 化試験 Lλ」L嵯勇 表4 リパーゼ活性阻 果 表5 施1 比較 表7 黄色ブドウ球 に対 6′ P。(Margin below) Shu IX Shiki” Table 3 Converting test Lλ” L Keiyu Table 4 Lipase activity inhibition Fruit Table 5 Example 1 Comparison Table 7 yellow grape bulb against 6' P.
に対
る
力
O: 菌の増殖を認めない
Δ; 菌の増殖をやや認める
×: 菌の増殖を認める
試料濃度とは、抗菌力試験の操作中での試料と蒸留水の
割合である。例えば、試料濃度60%は。Force against O: No bacterial growth Δ; Slight bacterial growth ×: The sample concentration at which bacterial growth is observed is the ratio of the sample to distilled water during the antibacterial activity test operation. For example, the sample concentration is 60%.
試料と蒸留水の比率が6:4で混合し測定したものであ
る。The sample and distilled water were mixed at a ratio of 6:4 and measured.
表8 ヒスタミン遊離抑 果 9 流側 比 伊 森」」シ斑」uL重 50人中30Å以上に効果があつ池 50人中20Å以上に効果があった。Table 8 Histamine release inhibition Fruit 9 Stream side Philippines and Italy “Mori” “Shima” uL heavy A pond that is effective for 30 Å or more out of 50 people It was effective for more than 20 Å out of 50 people.
50人中10Å以上に効果があった。It was effective for more than 10 Å out of 50 people.
50人中10Å以下に効果があった。It was effective in less than 10 Å out of 50 people.
Claims (1)
症効果を有する化粧料。A cosmetic having an anti-inflammatory effect characterized by containing potassium alum and acid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP63265034A JP2530488B2 (en) | 1988-10-20 | 1988-10-20 | Cosmetics |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP63265034A JP2530488B2 (en) | 1988-10-20 | 1988-10-20 | Cosmetics |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH02111714A true JPH02111714A (en) | 1990-04-24 |
JP2530488B2 JP2530488B2 (en) | 1996-09-04 |
Family
ID=17411669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP63265034A Expired - Lifetime JP2530488B2 (en) | 1988-10-20 | 1988-10-20 | Cosmetics |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2530488B2 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2715066A1 (en) * | 1994-01-17 | 1995-07-21 | Dargoire Laboratoire Philippe | Soap holder with permeable plate in contact with soap |
KR19990048303A (en) * | 1997-12-09 | 1999-07-05 | 성재갑 | Cosmetic soap composition |
US6139824A (en) * | 1998-07-17 | 2000-10-31 | L'oreal S.A. | Deodorant composition |
JP2002326942A (en) * | 2001-05-07 | 2002-11-15 | Nonogawa Shoji Kk | Preparation for external use for skin |
JP2004196828A (en) * | 1994-12-28 | 2004-07-15 | L'oreal Sa | Composition for treating hypersensitive skin |
JP2004224704A (en) * | 2003-01-20 | 2004-08-12 | Nonogawa Shoji Kk | Bathing agent composition |
KR100863617B1 (en) * | 2007-04-19 | 2008-10-15 | 바이오스펙트럼 주식회사 | Compositions for improving skin conditions comprising alum |
WO2010005403A1 (en) * | 2008-07-07 | 2010-01-14 | Yigit Kazim Ozguven | Dermatological composition for use in the treatment and/or prevention of skin diseases |
WO2014071426A1 (en) * | 2012-11-06 | 2014-05-15 | Gl & Partners Og | Alum for treating skin diseases |
JP2018150266A (en) * | 2017-03-13 | 2018-09-27 | 日本メナード化粧品株式会社 | Skin external preparation for preventing and/or improving pimples |
KR102104214B1 (en) * | 2019-12-24 | 2020-04-23 | 오한상 | Cosmetic composition comprising potassium alum |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5962516A (en) * | 1982-04-01 | 1984-04-10 | ジヨルジユ・レミ・ガストン・オリビエ | Perspiration treating composition |
-
1988
- 1988-10-20 JP JP63265034A patent/JP2530488B2/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5962516A (en) * | 1982-04-01 | 1984-04-10 | ジヨルジユ・レミ・ガストン・オリビエ | Perspiration treating composition |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2715066A1 (en) * | 1994-01-17 | 1995-07-21 | Dargoire Laboratoire Philippe | Soap holder with permeable plate in contact with soap |
JP2004196828A (en) * | 1994-12-28 | 2004-07-15 | L'oreal Sa | Composition for treating hypersensitive skin |
KR19990048303A (en) * | 1997-12-09 | 1999-07-05 | 성재갑 | Cosmetic soap composition |
US6139824A (en) * | 1998-07-17 | 2000-10-31 | L'oreal S.A. | Deodorant composition |
JP2002326942A (en) * | 2001-05-07 | 2002-11-15 | Nonogawa Shoji Kk | Preparation for external use for skin |
JP2004224704A (en) * | 2003-01-20 | 2004-08-12 | Nonogawa Shoji Kk | Bathing agent composition |
KR100863617B1 (en) * | 2007-04-19 | 2008-10-15 | 바이오스펙트럼 주식회사 | Compositions for improving skin conditions comprising alum |
WO2008130130A1 (en) * | 2007-04-19 | 2008-10-30 | Biospectrum, Inc. | Compositions for improving skin conditions comprising alum |
WO2010005403A1 (en) * | 2008-07-07 | 2010-01-14 | Yigit Kazim Ozguven | Dermatological composition for use in the treatment and/or prevention of skin diseases |
WO2014071426A1 (en) * | 2012-11-06 | 2014-05-15 | Gl & Partners Og | Alum for treating skin diseases |
JP2018150266A (en) * | 2017-03-13 | 2018-09-27 | 日本メナード化粧品株式会社 | Skin external preparation for preventing and/or improving pimples |
KR102104214B1 (en) * | 2019-12-24 | 2020-04-23 | 오한상 | Cosmetic composition comprising potassium alum |
Also Published As
Publication number | Publication date |
---|---|
JP2530488B2 (en) | 1996-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH05339138A (en) | Use of alpha-hydroxy fatty acid and composition containing the same | |
EP0998264A1 (en) | Composition comprising a lipoaminoacid and a tannin-rich plant extract | |
JP6089152B2 (en) | Exfoliating hair retention promoting formulation | |
JPH02111714A (en) | Cosmetic | |
JP2000136123A (en) | Skin lotion | |
JP2008239545A (en) | Elastase deactivator | |
JP2007223935A (en) | Skin care preparation | |
WO2018180460A1 (en) | Trpa1 activity inhibitor | |
US11045471B2 (en) | Melanin production inhibitor, whitening agent, fibroblast activator, collagen and/or elastin production promotor and wrinkle ameliorant | |
JP4681132B2 (en) | Nitric oxide synthase production promoter and cosmetic or pharmaceutical composition | |
JPH11286423A (en) | Composition for suppressing body odor | |
WO2016039407A1 (en) | Moisturizer and cosmetic containing same | |
JPH05271046A (en) | Dermal medicine for external use | |
FR2771633A1 (en) | SYNERGISTIC COMPOSITION COMPRISING AT LEAST ONE N-OCTANYL AMINOACIDE AND AT LEAST ONE N-UNDECYLENOYL AMINOACIDE; COSMETIC APPLICATION | |
JPH0532556A (en) | Skin agent for external use | |
JP4887050B2 (en) | Inadequate keratinization inhibitor, pore reducing agent | |
JP2011241166A5 (en) | ||
JP2011241166A (en) | Composition | |
JP2006176440A (en) | Bleaching or aging-preventing agent composition for skin and cosmetic | |
JPH04187618A (en) | Skin external preparation | |
JPH04187610A (en) | Cosmetics | |
JP5908678B2 (en) | Skin preparation | |
JP4222973B2 (en) | Elastase activity inhibitors and cosmetics | |
JP2004010505A (en) | Cosmetic | |
JP2006282536A (en) | Super oxide-eliminating agent, free radical-eliminating agent, hydrogen peroxide-eliminating agent and external preparation for skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090614 Year of fee payment: 13 |